ende

Because medical advances need a strong partner.

Funding is limited, especially for research projects in the area of Investigator Initiated Trials (IITs). But often there are interesting non-commercial studies that are essential for clinical research and for the further development and improvement of existing therapy concepts in day-to-day clinical practice – and in particular for the optimisation of patient treatment.

Regulatory requirements and the number of involved partners mean that research projects are becoming increasingly complex. At the IKF, we offer you the “space” for your research, link you up with relevant academic partners, and help you to stay in control during the research process. At every important step. With the organisation, the data, the workload, funding issues, the administration and the application process.

What we offer

    • Identification of anticipated costs and funding requirements
    • Financing and securing funding – in particular through applications for third-party funding and earmarked donations
    • Application for approvals and ethics committee opinions
    • Contract and project management as well as study coordination and controlling in line with the provisions of Good Clinical Practice (GCP), under the AMG [German Medicinal Products Act], the MPG [German Medical Devices Act] and professional law
    • Assistance with the statistical evaluation
    • Ensuring the best possible data quality and patient safety
    • Scientific supervision and support by our Advisory Board

Current research projects

The process of statistical consultancy and presentation, as well as evaluation of your research project:

1.
Give us an outline of your research idea.

2.
Together, we will formulate the specifics of your project and create the funding plan.

3.
We will support you in applying for approvals and ethics committee opinions.

4.
You start your research.

Publications

Filters
Reset
Reset
Reset

[Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma]

Authors: Frost N, Wesseler C, Wörmann B, Eberhardt WEE
Journal: Pneumologie . 2024 Apr;78(4):233-235.

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Authors: Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M
Journal: Eur J Cancer . 2024 Dec:213:115065.

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Authors: Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group
Journal: JTO Clin Res Rep . 2023 Dec 25;5(4):100626.

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

Authors: Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi SMS, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild SI, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik JL, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C
Journal: Int J Mol Sci . 2024 Apr 3;25(7):3992.